This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Reiter, F. Articles by Provinciali, L. Search for Related Content PubMed Articles by Reiter, F. Articles by Provinciali, L. Social Bookmarking                         What's this?

Disability Changes After Treatment of Upper Limb Spasticity with Botulinum Toxin

Neurorehabilitation Department, University of Ancona, Ancona, Italy

Maura Danni

Neurorehabilitation Department, University of Ancona, Ancona, Italy

M. Gabriella Ceravolo

Neurorehabilitation Department, University of Ancona, Ancona, Italy

Leandro Provinciali

Neurorehabilitation Department, University of Ancona, Ancona, Italy

We performed an open label single-blind trial with seventeen patients with moderate to severe upper limb spasticity following stroke or traumatic brain injury, treated with an average dose of 165 MU (mouse units) botulinum toxin (range: 100 MU to 210 MU). Evaluation of outcome was carried out analyzing the changes in standard mea sures of impairment, disability, and quality of life. Spasticity reduction, with increased range of motion (ROM), was observed in all patients, independent of the duration of spasticity. Changes either in "focal" or in "global" disability scores occurred in two sub groups of subjects showing, respectively, residual motor function of the extensor mus cles or severe spasticity-related disability. Patients with no residual motricity of the antagonist muscles at the spastic limb, with moderate spasticity, scoring high values on the Functional Independence Measure (FIM) assessment, did not show any disabil ity decrease after treatment. These findings stress the need for an accurate assessment of the patient's impairment and disability to optimize the cost/benefit ratio of BTX appli cation.

Key Words: Key Words: Spasticity—Botulinum toxin—Assessment—Disability.

Neurorehabilitation and Neural Repair, Vol. 10, No. 1, 47-52 (1996)
DOI: 10.1177/154596839601000107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?